Immunovant, Inc. financial data

Symbol
IMVT on Nasdaq
Location
320 West 37 Th Street, New York, NY
Fiscal year end
March 31
Latest financial report
10-Q - Q2 2025 - Aug 11, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 912 % -33%
Debt-to-equity 12.1 % +52.8%
Return On Equity -84.5 % -62.3%
Return On Assets -75.4 % -56.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 174M shares +19.1%
Common Stock, Shares, Outstanding 171M shares +17%
Entity Public Float 1.87B USD -14.3%
Common Stock, Value, Issued 16K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 171M shares +17%
Weighted Average Number of Shares Outstanding, Diluted 171M shares +17%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 84.5M USD +39.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -446M USD -63.9%
Income Tax Expense (Benefit) 1.73M USD +164%
Net Income (Loss) Attributable to Parent -447M USD -64.1%
Earnings Per Share, Basic -2 USD/shares -48.7%
Earnings Per Share, Diluted -2 USD/shares -48.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 599M USD +6.95%
Accounts Receivable, after Allowance for Credit Loss, Current 1.94M USD -19.9%
Assets, Current 652M USD +10.6%
Property, Plant and Equipment, Net 737K USD +30.4%
Operating Lease, Right-of-Use Asset 98K USD -26.3%
Other Assets, Noncurrent 8.94M USD
Assets 661M USD +12.2%
Accounts Payable, Current 7.84M USD -28.9%
Accrued Liabilities, Current 50.7M USD +22.9%
Liabilities, Current 52.9M USD +17.5%
Operating Lease, Liability, Noncurrent 0 USD -100%
Liabilities 52.9M USD +17.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.74M USD -4.56%
Retained Earnings (Accumulated Deficit) -1.36B USD -49%
Stockholders' Equity Attributable to Parent 609M USD +11.7%
Liabilities and Equity 661M USD +12.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -117M USD -54.1%
Net Cash Provided by (Used in) Financing Activities 2.92M USD +325%
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 171M shares +17%
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -115M USD -52.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 599M USD +6.95%
Deferred Tax Assets, Valuation Allowance 219M USD +54.6%
Deferred Tax Assets, Gross 220M USD +55%
Operating Lease, Liability 138K USD -88.7%
Depreciation 107K USD +33.8%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -447M USD -64.6%
Lessee, Operating Lease, Liability, to be Paid 141K USD -88.7%
Operating Lease, Liability, Current 98K USD -29%
Lessee, Operating Lease, Liability, to be Paid, Year One 141K USD -88.2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3K USD -88%
Deferred Tax Assets, Operating Loss Carryforwards 153M USD +56.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Additional Paid in Capital 1.97B USD +35.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 1.1M USD +216%
Share-based Payment Arrangement, Expense 54.4M USD +24.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%